Polyvalent Nucleic Acid Nanoparticles for Genetic Delivery |
| David Giljohann
AuraSense
|
Dr. Giljohann received his BA and Ph.D. degrees from Northwestern University (2003, 2009) and currently holds an appointment as a Postdoctoral Fellow at the International Institute of Nanotechnology. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including Nano-flares and antisense DNA and siRNA gold nanoparticles. Dr. Giljohann has been collaborating extensively with physicians in the clinical setting to translate these technologies into impactful materials to improve human health. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He has contributed to over 20 manuscripts and multiple patents and applications. In his role at AuraSense, Dr. Giljohann is leading scientific partnerships efforts to move AuraSense technologies to commercialization.